Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

225 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-01

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

DRPLA Natural History and Biomarkers Study (DRPLA NHBS) is a prospective observational study that will lay the foundation for clinical trials in DRPLA. The aims of this project are:

* To characterize the natural history of DRPLA in both juvenile- and adult-onset patients and study different modalities of biomarkers in this condition.
* To identify genetic factors and biomarkers that could predict disease progression.
* To provide a platform to support the design and conduct of clinical trials.

This study has three arms:

1. Adult Participants: this arm of the study will require participants to be 16 years old or over to participate.
2. Pediatric Participants: this arm of the study will require participants to be under 16 years old to participate.
3. Remote Participants: patients that cannot or do not wish to travel to one of the study sites can participate in this arm of the study, irrespective of their age.

Participants will have an annual visit for three years (baseline visit and two follow-up visits, three visits in total). Subjects who complete the whole protocol will be assessed on two consecutive days to reduce patient burden.

This project will allow for a better understanding of DRPLA and its course, and therefore allow for future clinical trials on this condition to be more precisely and effectively conducted.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids

NCT00709579

Cortico Atrophy

UNKNOWN PHASE3

Genotype-phenotype Correlation in Junctional Epidermolysis Bullosa

NCT04727268

Junctional Epidermolysis Bullosa Laryngo Onycho Cutaneous Syndrome

UNKNOWN

Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa

NCT01768026

Dystrophic Epidermolysis Bullosa

WITHDRAWN

Early Detection and Follow-Up of Patients With Fabry's Disease

NCT04847713

Fabry's Disease

UNKNOWN

Short Term Observational Study in DEB Patients

NCT02178969

Dystrophic Epidermolysis Bullosa

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dentatorubral-Pallidoluysian Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DRPLA-mutation carrier

Subjects with a positive genetic test for a pathological expansion in the ATN1 gene.

Positive genetic test for pathological expansion in ATN1

Intervention Type OTHER

Positive genetic test for pathological expansion in ATN1

Volunteer control

Subjects without neurological conditions (other than primary headache disorders), without a family history of DRPLA or a previous negative genetic test for pathological expansions in the ATN1 gene.

Positive genetic test for pathological expansion in ATN1

Intervention Type OTHER

Positive genetic test for pathological expansion in ATN1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Positive genetic test for pathological expansion in ATN1

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. DRPLA adult participants must be 16 years old or over at the time of enrollment, to participate.
2. DRPLA adult participants must have a genetic diagnosis of DRPLA and CAG repeat expansion \>35.
3. Patient is able to read, understand, and provide written informed consent (signed and dated). If the patient is under the age of 18 or is unable to provide consent, the patient must have a parent or caregiver capable of providing informed consent (signed and dated) and able to attend all scheduled study visits, and provide feedback regarding the participant's symptoms and performance as described in the protocol.
4. Adult pre-symptomatic subjects must have a positive genetic test for the DRPLA expansion without symptoms compatible with the disease, and be 16 years old or over at the time of enrollment.
5. Adult Family/Community control participants must be 16 years old or over at the time of enrollment to participate. Blood-relatives must not have a genetic diagnosis of DRPLA or their genetic status is unknown.

a. DRPLA pediatric participants must be under 16 years old at the time of enrollment, to participate.

f. DRPLA pediatric participants must have a genetic diagnosis of DRPLA and CAG repeat expansion \>35.

g. If the patient is under the age of 18 or is unable to provide consent, the patient must have a parent or caregiver capable of providing informed consent (signed and dated) and able to attend all scheduled study visits, and provide feedback regarding the participant's symptoms and performance as described in the protocol.

h. Pediatric Family/Community control participants must be under 16 years old at the time of enrollment to participate. Blood-relatives must not have a genetic diagnosis of DRPLA or their genetic status is unknown.

Exclusion Criteria

1. Individuals with an ataxia condition other than DRPLA.
2. Failure to sign the consent form will result in study exclusion.
3. Has any condition or circumstance that, in the opinion of the Investigator, makes the participant unsuitable for enrolment. These may include medical conditions which might affect the measurement of biomarkers.
4. Participants will be excluded from the lumbar puncture, and skin biopsy procedures if they have a history of severe allergic or anaphylactic reactions or other adverse reactions to local anesthetics used in the study.
5. For family/community controls: those individuals with neurological conditions (other than primary headache disorders) will be excluded.

f. Individuals with an ataxia condition other than DRPLA. g. Failure to sign the consent form will result in study exclusion. h. Has any condition or circumstance that, in the opinion of the Investigator, makes the participant unsuitable for enrolment. These may include medical conditions which might affect the measurement of biomarkers.

i. Participants will be excluded from the lumbar puncture, and skin biopsy procedures if they have a history of severe allergic or anaphylactic reactions or other adverse reactions to local anesthetics used in the study.

j. For family/community controls: those individuals with neurological conditions (other than primary headache disorders) will be excluded.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes